Latest Pharmaceutical drug Stories

Growing Prevalence of Asthma is Fueling Vigorous Industry Competition for Effective, Affordable Therapies

2012-09-17 06:28:37

NEW YORK, Sept. 17, 2012 /PRNewswire/ -- Citeline(®), an Informa business, reviewed clinical trial data presented at the European Respiratory Society (ERS) conference, held September 1-5, 2012 in Vienna, Austria, noting that classical fixed-dose combination (FDC) treatments remain a focus of industry sponsors, but that novel targeted asthma drugs may also be on the horizon for persistent asthma patients. (Logo: http://photos.prnewswire.com/prnh/20120917/NE75453LOGO ) Respiratory...

PhRMA Statement on Proposed Changes to Medicaid in Louisiana

2012-09-12 10:25:37

WASHINGTON, Sept. 12, 2012 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today on proposed changes to Medicaid in Louisiana: (Logo: http://photos.prnewswire.com/prnh/20091027/PHRMALOGO ) "Seeking new approaches to coordinate care for Medicaid and LaCHIP recipients is critically important. However, without proper protections for patients, the Louisiana Department of Health...

Genelex Corporation Rolls Out Lifesaving DNA Healthcare System

2012-09-12 06:31:36

SEATTLE, Sept. 12, 2012 /PRNewswire/ -- A new medical test system announced today by Genelex Corporation could save thousands of lives and reduce annual healthcare costs by hundreds of millions of dollars by preventing adverse reactions to prescribed and over-the-counter drugs. "YouScript is the most comprehensive prescription drug management system ever created, able to clearly define what drugs and combinations of drugs a person should - and should not - be prescribed, not only...

Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY

2012-09-12 06:31:02

BASKING RIDGE, N.J., Sept. 12, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the UBS Global Life Sciences Conference at 2:00 p.m. ET on September 19, 2012 at the Grand Hyatt in New York City. The presentation will include an overview of the Company's pipeline with emphasis on the lead development program,...

Circassia Appoints Dr Brett Haumann as Chief Medical Officer

2012-09-10 22:23:22

OXFORD, England, September 11, 2012 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Dr Brett Haumann as Chief Medical Officer. Dr Haumann joins Circassia from GlaxoSmithKline where he was Vice President and Medicines Development Leader responsible for the late-stage development of once-daily inhaled medicines for the treatment of asthma and COPD. "I am delighted Brett has chosen to join...

AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents

2012-09-10 02:29:42

LONDON and CAMBRIDGE, Mass., Sept. 10, 2012 /PRNewswire/ -- AstraZeneca and the Broad Institute in Cambridge, Massachusetts today announce a collaboration to identify new chemical compounds targeting bacterial and viral infections that could speed the development of new antibacterial and antiviral drugs. Bacterial and viral infections remain a significant global health concern; according to the World Health Organisation's 'Global Burden of Disease' report, infectious and parasitic...

Imprimis Names Two Experts To Its Science And Regulatory Board

2012-09-10 02:28:57

SOLANA BEACH, Calif., Sept. 10, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. today announced the appointment of two new members of its Science and Regulatory Advisory Board - Drs. Lee S. Simon and Allan Green, who both have extensive experience in the pharmaceutical industry, particularly with regard to the U.S. Food and Drug Administration's approval process. Simon and Green will join Dr. Gerald Yakatan on the advisory board, whose first task will be to provide advice and...

Strategic Agreement Launches Novel Drug Development Model

2012-09-07 02:23:48

SOLANA BEACH, Calif., Sept. 7, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY: OTCQB) today announced a strategic development and investment agreement with Houston-based Professional Compounding Centers of America, Inc. (PCCA). The agreement will allow the companies to develop and share drug-formulation technology, with the goal of creating a new generation of treatments for muscle and joint pain, neuropathic pain and other conditions. PCCA also made a $4 million equity...

Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca

2012-09-07 02:23:38

CRANBURY, N.J., Sept. 7, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner, AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity. AstraZeneca remains committed to this collaboration program and to the continued advancement of melanocortin agonists for treatment of obesity. AZD2820, a...

HealthWarehouse.com Reports 38% Year-Over-Year Revenue Growth in the First Quarter 2012

2012-09-05 14:23:39

CINCINNATI, Sept. 5, 2012 /PRNewswire/ -- HealthWarehouse.com, Inc. (OTC: HEWA) a leading VIPPS accredited retail mail-order pharmacy, today announced its financial results for the first quarter ended March 31, 2012. In the first quarter of 2012, the Company's quarterly net sales increased to $3,153,607 from $2,284,552, up 38% compared to the same period in 2011. Selling, general and administrative expenses (SG&A) increased by $730,780 in the first quarter of 2012 compared...